Patents by Inventor Yaping Yang

Yaping Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12026466
    Abstract: A method for entity relations extraction including applying entity markers to a set of sentences included in a data bag to generate a token sequence for a subset of the set of sentences, the token sequence including a beginning position mark and an ending position mark of a corresponding sentence, as well as a front position mark and a rear position mark of at least one entity included in each of the subset of the set of sentences; using the generated token sequences of the set of sentences with a pre-trained language representation model to generate a sentence feature vector for each sentence included in the data bag; aggregating, in a data encoding module, the sentence feature vectors of the set of sentences into a bag encoding vector; and classifying data entity relations of the set of sentences included in the data bag through decoding and inferencing the bag encoding vector.
    Type: Grant
    Filed: March 13, 2023
    Date of Patent: July 2, 2024
    Assignee: AILIFE DIAGNOSTICS, INC.
    Inventors: Yaping Yang, Weizhi Xu, Jiran Zhu, Xia Wang, Hui Yu
  • Publication number: 20240052037
    Abstract: The present invention provides an anti-PD-L1/anti-CD47 bispecific antibody and a preparation method therefor. The antibody has characteristics of a natural IgG, and is a highly stable heterodimeric form without heavy and light chain mismatching. The bispecific antibody can bind two target molecules at the same time and has a smaller side effect.
    Type: Application
    Filed: January 7, 2022
    Publication date: February 15, 2024
    Inventors: Jiawang LIU, Yaping YANG, Siqi ZHAO, Yang LIU, Nanmeng SONG, Hongjuan ZHANG, Dongxue YANG, Lanxin ZHANG, Jing WANG, Jiangcheng XU, Kyoung Woo LEE
  • Publication number: 20240034801
    Abstract: Provided are an anti-PD-L1/anti-4-1BB natural antibody structure-like heterodimeric form bispecific antibody and a preparation thereof. Specifically, provided are an anti-PD-L1/anti-4-1BB bispecific antibody that has natural IgG features, that has no mismatch between heavy and light chains and that is in the form of a highly stable heterodimer, as well as a preparation method therefor. The bispecific antibody can simultaneously bind two target molecules and is more effective in treating complex diseases and has fewer side effects.
    Type: Application
    Filed: January 7, 2022
    Publication date: February 1, 2024
    Inventors: Jiawang LIU, Yaping YANG, Siqi ZHAO, Yang LIU, Nanmeng SONG, Fei FAN, Kaixuan SU, Lanxin ZHANG, Jing WANG, Jiangcheng XU, Kyoung Woo LEE
  • Patent number: 11827697
    Abstract: An anti-PD-1/anti-VEGF natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof. Provided are a highly stable, heterodimeric form anti-PD-1/anti-VEGF bispecific antibody having natural IgG characteristics and free of mismatched heavy and light chains and preparation method for the antibody. The bispecific antibody is capable of simultaneously binding with two target molecules and provides improved efficacy in treating a complicated disease.
    Type: Grant
    Filed: February 2, 2019
    Date of Patent: November 28, 2023
    Assignee: Beijing Hanmi Pharmaceutical Co., Ltd.
    Inventors: Yaping Yang, Nanmeng Song, Wenchu Xiao, Zhenlei Li, Lina Zhang, Mingyue Gu, Chunguang Zhan, Jiawang Liu, Maengsup Kim
  • Patent number: 11753471
    Abstract: Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. More particularly, provided are a highly stable heterodimeric anti-PD-1/anti-HER2 bispecific antibody having natural IgG characteristics without mismatch between a heavy chain and a light chain, and a method of preparing the same. The bispecific antibody may bind to two target molecules simultaneously and has excellent effects in treatment of a complex disease.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: September 12, 2023
    Assignees: BEIJING HANMI PHARMACEUTICAL CO., LTD., INNOVENT BIOLOGICS (SUZHOU) CO., LTD.
    Inventors: Jiawang Liu, Nanmeng Song, Yaping Yang, Maeng Sup Kim, Yao Yan, Qingqing Yin
  • Patent number: 11739151
    Abstract: Provided are an anti-PD-L1/anti-CD47 bispecific antibody that has natural IgG characteristics and is in a highly stable heterodimer form without the heavy chain and light chain being mismatched, and a preparation method therefor. Either the first Fc chain or second Fc chain of the bispecific antibody comprises amino acid substitutions at positions 366 and 399, and the other comprises amino acid substitutions at positions 351, 407 and 409.
    Type: Grant
    Filed: December 1, 2018
    Date of Patent: August 29, 2023
    Assignee: Beijing Hanmi Pharmaceutical Co., Ltd.
    Inventors: Jiawang Liu, Yaping Yang, Nanmeng Song, Maengsup Kim
  • Patent number: 11591409
    Abstract: Provided are an anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and a preparation thereof. In particular, provided are a highly stable heterodimeric anti-PD-L1/anti-PD-1 bispecific antibody with characteristics of a natural IgG and without mismatches heavy chain-light chain, and a preparation thereof. The bispecific antibody can bind to both target molecules and is more effective in treating a complex disease.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: February 28, 2023
    Assignee: BEIJING HANMI PHARM. CO., LTD.
    Inventors: Jiawang Liu, Nanmeng Song, Yaping Yang, Mengxie Jin
  • Patent number: 11498977
    Abstract: The present invention provides a method for production of stable and highly specific heterodimeric immunoglobulin constructs, e.g., bispecific antibodies, retaining desirable properties of native IgG and lacking undesirable heavy chain-light chain mispairing, that can simultaneously bind two target molecules and are more potent in the treatment of complex diseases.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: November 15, 2022
    Assignee: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Jiawang Liu, Nanmeng Song, Dongge Yang, Yaping Yang, Maengsup Kim
  • Publication number: 20220176274
    Abstract: The present disclosure provides a method of separating hematopoietic stem cells from umbilical cord blood, including the following steps: a hydroxyethyl starch solution is added into cord blood and mixed uniformly, then centrifuged to get an upper liquid layer and a lower erythrocyte layer; the liquid in the upper layer and the erythrocytes in the lower layer are centrifuged respectively; an upper plasma layer and a basal cell layer are obtained after the centrifugation of the upper liquid layer, the cells in the basal layer are resuspended; a superficial buffy-coat layer is obtained after the centrifugation of the erythrocytes, and the superficial buffy-coat layer is metered with the plasma in the upper layer, and then centrifuged to get a lower cell layer, which is precipitated to remove erythrocytes and then resuspended; the above resuspended cells are added into freezing medium, mixed uniformly and then stored in a liquid nitrogen tank.
    Type: Application
    Filed: June 17, 2021
    Publication date: June 9, 2022
    Inventors: Cheng Wang, Yaping Yang, Yu Liao, Lang Zhang, Dan Wang
  • Patent number: 11319378
    Abstract: Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. Specifically, provided are a highly stable anti-PD-1/anti-HER2 heterodimeric bispecific antibody having characteristics of a natural IgG and having no mismatched heavy chain and light chain, and a method of preparing the same. The bispecific antibody may bind to both of two kinds of target molecules, and thus may be more effective in treating complex diseases.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: May 3, 2022
    Assignee: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Jiawang Liu, Nanmeng Song, Yaping Yang, Maengsup Kim
  • Publication number: 20220010006
    Abstract: Provided are an anti-TNF?/anti IL-17A natural antibody structure-like heterodimer form of a bispecific antibody and a preparation method therefor, wherein the antibody can bind two target molecules simultaneously, and can be used for treating complex diseases.
    Type: Application
    Filed: November 5, 2019
    Publication date: January 13, 2022
    Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Jiawang LIU, Yaping YANG, Nanmeng SONG, Wenchu XIAO, Chulwoong CHUNG, Maengsup KIM
  • Patent number: 11117967
    Abstract: An antibody specifically binding to PD-1 and a functional fragment thereof. The antibody or functional fragment thereof includes a PD-1 chimeric antibody and a functional fragment thereof, and a PD-1 humanized antibody and a functional fragment thereof.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: September 14, 2021
    Assignee: BEIJING HANMI PHARM. CO., LTD.
    Inventors: Yaping Yang, Jiawang Liu, Nanmeng Song, Hongjuan Zhang, Mengxie Jin
  • Publication number: 20210230277
    Abstract: Provided are an anti-PD-L1/anti-CD47 bispecific antibody that has natural IgG characteristics and is in a highly stable heterodimer form without the heavy chain and light chain being mismatched, and a preparation method therefor. Either the first Fc chain or second Fc chain of the bispecific antibody comprises amino acid substitutions at positions 366 and 399, and the other comprises amino acid substitutions at positions 351, 407 and 409.
    Type: Application
    Filed: December 1, 2018
    Publication date: July 29, 2021
    Inventors: Jiawang Liu, Yaping Yang, Nanmeng Song, Maengsup Kim
  • Patent number: 11072052
    Abstract: A guard assembly for an abrasive accessory of a power tool is provided, including a guard shell being associated with a first surface of the abrasive accessory and secured to the power tool around an output spindle of the power tool; and a guard cover being associated with a second surface of the abrasive accessory opposite the first surface and attached to the guard shell at a pivot point having an axis that is at a distance from an axis of the spindle, the guard cover being rotatably movable with respect to the guard shell around the pivot point.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: July 27, 2021
    Assignee: Black & Decker Inc.
    Inventors: Joshua J. Aiken, Qingyang Li, Peter Chaikowsky, Sean M. Kelly, Yaping Yang
  • Patent number: 11072651
    Abstract: An antibody specifically binding to IL-17A or a functional fragment thereof. The antibody or functional fragment thereof includes an IL-17A chimeric antibody and a functional fragment thereof, and an IL-17A humanized antibody and a functional fragment thereof.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: July 27, 2021
    Assignee: BEIJING HANMI PHARM. CO., LTD.
    Inventors: Nanmeng Song, Jiawang Liu, Yaping Yang, Yang Yang, Dongge Yang, Hongjuan Zhang, Mengxie Jin
  • Publication number: 20210040193
    Abstract: An anti-PD-1/anti-VEGF natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof. Provided are a highly stable, heterodimeric form anti-PD-1/anti-VEGF bispecific antibody having natural IgG characteristics and free of mismatched heavy and light chains and preparation method for the antibody. The bispecific antibody is capable of simultaneously binding with two target molecules and provides improved efficacy in treating a complicated disease.
    Type: Application
    Filed: February 2, 2019
    Publication date: February 11, 2021
    Inventors: Yaping Yang, Nanmeng Song, Wenchu Xiao, Zhenlei Li, Lina Zhang, Mingyue Gu, Chunguang Zhan, Jiawang Liu, Maengsup Kim
  • Publication number: 20210032343
    Abstract: Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. More particularly, provided are a highly stable heterodimeric anti-PD-1/anti-HER2 bispecific antibody having natural IgG characteristics without mismatch between a heavy chain and a light chain, and a method of preparing the same. The bispecific antibody may bind to two target molecules simultaneously and has excellent effects in treatment of a complex disease.
    Type: Application
    Filed: February 8, 2019
    Publication date: February 4, 2021
    Applicants: BEIJING HANMI PHARMACEUTICAL CO., LTD., INNOVENT BIOLOGICS (SUZHOU) CO., LTD.
    Inventors: Jiawang LIU, Nanmeng SONG, Yaping YANG, Maeng Sup KIM, Yao YAN, Qingqing YIN
  • Publication number: 20200299412
    Abstract: Provided are an anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and a preparation thereof. In particular, provided are a highly stable heterodimeric anti-PD-L1/anti-PD-1 bispecific antibody with characteristics of a natural IgG and without mismatches heavy chain-light chain, and a preparation thereof. The bispecific antibody can bind to both target molecules and is more effective in treating a complex disease.
    Type: Application
    Filed: March 28, 2018
    Publication date: September 24, 2020
    Applicant: BEIJING HANMI PHARM. CO., LTD.
    Inventors: Jiawang Liu, Nanmeng Song, Yaping Yang, Mengxie Jin
  • Publication number: 20190367633
    Abstract: Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. Specifically, provided are a highly stable anti-PD-1/anti-HER2 heterodimeric bispecific antibody having characteristics of a natural IgG and having no mismatched heavy chain and light chain, and a method of preparing the same. The bispecific antibody may bind to both of two kinds of target molecules, and thus may be more effective in treating complex diseases.
    Type: Application
    Filed: November 16, 2017
    Publication date: December 5, 2019
    Applicant: BEIJING HANMI PHARMACEUTICAL CO., LTD.
    Inventors: Jiawang LIU, Nanmeng SONG, Yaping YANG, Maengsup KIM
  • Publication number: 20190367615
    Abstract: An antibody specifically binding to PD-1 and a functional fragment thereof. The antibody or functional fragment thereof includes a PD-1 chimeric antibody and a functional fragment thereof, and a PD-1 humanized antibody and a functional fragment thereof.
    Type: Application
    Filed: September 8, 2017
    Publication date: December 5, 2019
    Inventors: Yaping Yang, Jiawang Liu, Nanmeng Song, Hongjuan Zhang, Mengxie Jin